179 related articles for article (PubMed ID: 29119413)
1. Identification and Characterization of Fenofibrate-Induced Liver Injury.
Ahmad J; Odin JA; Hayashi PH; Chalasani N; Fontana RJ; Barnhart H; Cirulli ET; Kleiner DE; Hoofnagle JH
Dig Dis Sci; 2017 Dec; 62(12):3596-3604. PubMed ID: 29119413
[TBL] [Abstract][Full Text] [Related]
2. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.
Nicoletti P; Aithal GP; Bjornsson ES; Andrade RJ; Sawle A; Arrese M; Barnhart HX; Bondon-Guitton E; Hayashi PH; Bessone F; Carvajal A; Cascorbi I; Cirulli ET; Chalasani N; Conforti A; Coulthard SA; Daly MJ; Day CP; Dillon JF; Fontana RJ; Grove JI; Hallberg P; Hernández N; Ibáñez L; Kullak-Ublick GA; Laitinen T; Larrey D; Lucena MI; Maitland-van der Zee AH; Martin JH; Molokhia M; Pirmohamed M; Powell EE; Qin S; Serrano J; Stephens C; Stolz A; Wadelius M; Watkins PB; Floratos A; Shen Y; Nelson MR; Urban TJ; Daly AK;
Gastroenterology; 2017 Apr; 152(5):1078-1089. PubMed ID: 28043905
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database.
Ma S; Liu S; Wang Q; Chen L; Yang P; Sun H
J Clin Pharm Ther; 2020 Feb; 45(1):204-207. PubMed ID: 31518450
[TBL] [Abstract][Full Text] [Related]
4. The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine.
Fontana RJ; Cirulli ET; Gu J; Kleiner D; Ostrov D; Phillips E; Schutte R; Barnhart H; Chalasani N; Watkins PB; Hoofnagle JH
J Hepatol; 2018 Dec; 69(6):1317-1325. PubMed ID: 30138689
[TBL] [Abstract][Full Text] [Related]
5. Acute cholestatic hepatitis induced by fenofibrate.
Hajdu D; Aiglová K; Vinklerová I; Urbánek K
J Clin Pharm Ther; 2009 Oct; 34(5):599-602. PubMed ID: 19744016
[TBL] [Abstract][Full Text] [Related]
6. [Acute cytolytic and cholestatic hepatitis induced by fenofibrate].
Pichon N; Vincensini JF; Rozière A; Labrousse F; Sautereau D; Pillegand B
Gastroenterol Clin Biol; 2003 Oct; 27(10):947-9. PubMed ID: 14631314
[No Abstract] [Full Text] [Related]
7. Liver injury caused by fenofibrate within 48 h after first administration: a case report.
He Y; Qin MZ; Chen YW
BMC Gastroenterol; 2021 Jul; 21(1):298. PubMed ID: 34325660
[TBL] [Abstract][Full Text] [Related]
8. Fenofibrate-induced acute cholestatic hepatitis.
Ho CY; Kuo TH; Chen TS; Tsay SH; Chang FY; Lee SD
J Chin Med Assoc; 2004 May; 67(5):245-7. PubMed ID: 15357112
[TBL] [Abstract][Full Text] [Related]
9. Clinical and histologic features of azithromycin-induced liver injury.
Martinez MA; Vuppalanchi R; Fontana RJ; Stolz A; Kleiner DE; Hayashi PH; Gu J; Hoofnagle JH; Chalasani N
Clin Gastroenterol Hepatol; 2015 Feb; 13(2):369-376.e3. PubMed ID: 25111234
[TBL] [Abstract][Full Text] [Related]
10. [Acute hepatitis and drug dermatitis due to fenofibrate (Secalip)].
Fartoux-Heymann L; Narcy-Lambare B; Labayle D; Fischer D
Ann Med Interne (Paris); 2001 Sep; 152(5):353-4. PubMed ID: 11593148
[No Abstract] [Full Text] [Related]
11. [Painful acute liver involvement related to ingestion of fenofibrate].
Rouhier ML; Rifflet H; Rifflet I; Oberti F; Vuillemin E; Chevailler A; Calès P
Gastroenterol Clin Biol; 1996; 20(12):1137-8. PubMed ID: 9033862
[No Abstract] [Full Text] [Related]
12. Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia.
Lee SH; Cho KI; Kim JY; Ahn YK; Rha SW; Kim YJ; Choi YS; Choi SW; Jeon DW; Min PK; Choi DJ; Baek SH; Kim KS; Byun YS; Jang Y
Atherosclerosis; 2012 Mar; 221(1):169-75. PubMed ID: 22269152
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and pathological features in 138 cases of drug-induced liver injury].
Lai RT; Wang H; Gui HL; Ye MZ; Dai WJ; Xiang XG; Zhao GD; Wang WJ; Xie Q
Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):185-9. PubMed ID: 22475136
[TBL] [Abstract][Full Text] [Related]
14. [Hepatitis caused by fenofibrate].
Massen H; Furet Y
Cah Anesthesiol; 1986 May; 34(3):249-50. PubMed ID: 3742311
[No Abstract] [Full Text] [Related]
15. Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor.
Urban TJ; Nicoletti P; Chalasani N; Serrano J; Stolz A; Daly AK; Aithal GP; Dillon J; Navarro V; Odin J; Barnhart H; Ostrov D; Long N; Cirulli ET; Watkins PB; Fontana RJ; ; ;
J Hepatol; 2017 Jul; 67(1):137-144. PubMed ID: 28323125
[TBL] [Abstract][Full Text] [Related]
16. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.
Ghabril M; Bonkovsky HL; Kum C; Davern T; Hayashi PH; Kleiner DE; Serrano J; Rochon J; Fontana RJ; Bonacini M;
Clin Gastroenterol Hepatol; 2013 May; 11(5):558-564.e3. PubMed ID: 23333219
[TBL] [Abstract][Full Text] [Related]
17. [Studies on the risk factors for fenofibrate-induced elevation of liver function tests].
Hayakawa T; Hayashi A; Miyakawa M; Shimoyama K; Sekiya S; Sekiguchi M; Inotsume N
Yakugaku Zasshi; 2002 Feb; 122(2):169-75. PubMed ID: 11857958
[TBL] [Abstract][Full Text] [Related]
18. [Hepatitis induced by fibrates].
Tudesq N; Bentournes M
Ann Biol Clin (Paris); 2006; 64(5):515-6. PubMed ID: 17124754
[No Abstract] [Full Text] [Related]
19. Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury.
Chalasani N; Li YJ; Dellinger A; Navarro V; Bonkovsky H; Fontana RJ; Gu J; Barnhart H; Phillips E; Lammert C; Schwantes-An TH; Nicoletti P; Kleiner DE; Hoofnagle JH;
J Hepatol; 2023 Feb; 78(2):293-300. PubMed ID: 36152763
[TBL] [Abstract][Full Text] [Related]
20. Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center.
Ettel M; Gonzalez GA; Gera S; Eze O; Sigal S; Park JS; Xu R
Hum Pathol; 2017 Oct; 68():92-98. PubMed ID: 28873351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
